GlassScriptPhysician profile
Michael J Neumann
NPI 1578549325
$6,402.81
in general payments reported to CMS, 2019-2025
30 companies · $994 in 2025
The $994 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,967 · 2020: $335 · 2021: $23.30 · 2022: $497 · 2023: $1,230 · 2024: $1,357 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,537 · Education: $43.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,536.70 |
| Education | $43.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,542.31 | 2019-2025 | |
| Pfizer INC. | $1,183.77 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $684.55 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $443.64 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $272.94 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $254.81 | 2023-2025 | Ocaliva |
| Genzyme Corporation | $203.62 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $186.94 | 2023 | Zeposia |
| Janssen Biotech, INC. | $180.11 | 2019-2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $177.19 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $175.43 | 2023-2024 | Dupixent |
| Madrigal Pharmaceuticals | $151.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $133.80 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $121.09 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $111.27 | 2024-2025 | Iqirvo, Bylvay |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $95.60 | 2023-2025 | Ibsrela |
| Ucb, INC. | $87.32 | 2019 | |
| Merck Sharp & Dohme LLC | $69.02 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $48.49 | 2024-2025 | |
| Organon LLC | $46.48 | 2023 | Renflexis, Hadlima |
| Phathom Pharmaceuticals, INC. | $45.77 | 2024 | Voquezna |
| Ferring Pharmaceuticals INC. | $34.27 | 2023 | Rebyota |
| Braintree Laboratories, INC. | $29.36 | 2023 | Sutab, Suflave |
| Fresenius Kabi USA, LLC | $28.21 | 2023 | |
| Celltrion USA INC. | $21.76 | 2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $18.31 | 2024 | |
| Intra-Sana Laboratories | $16.34 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.89 | 2023 | Cyltezo |
| Shionogi INC | $12.94 | 2019 | |
| Horizon Therapeutics Plc | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Neumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.